Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,859 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo IV infusion Clear all
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 5:32 PM EDT
Withdrawn Phase 3 Interventional

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

NCT02438852
View directory record Official record
Conditions
Bladder Carcinoma, Post-operative Pain
Interventions
Placebo, Questionnaire Administration, Ropivacaine Hydrochloride
Other · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

NCT04988152
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab, Placebo to Biologic
Biological · Other
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Anaheim, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

NCT04111666
View directory record Official record
Conditions
Healthy
Interventions
AL101, Placebo
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?

NCT00486902
View directory record Official record
Conditions
Ketamine Adverse Reaction, Effects of; Anesthesia, Spinal and Epidural, in Pregnancy, Complication of Labor and/or Delivery
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

NCT01941537
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ILV-094, Placebo Comparator
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 14, 2026, 5:32 PM EDT
Terminated Phase 2Phase 3 Interventional

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

NCT04367077
View directory record Official record
Conditions
ARDS
Interventions
MultiStem, Placebo
Biological
Lead sponsor
Healios K.K.
Industry
Eligibility
18 Years to 89 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • Akron, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 5:32 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Interventions
AOC-1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Orange, California • Palo Alto, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

NCT02110706
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants

NCT04971395
View directory record Official record
Conditions
Healthy Participants
Interventions
Placebo, XTMAB-16 2 mg/kg, XTMAB-16 4mg/kg
Drug
Lead sponsor
Xentria, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02740972
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
NS-065/NCNP-01, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Sacramento, California • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 14, 2026, 5:32 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

NCT07360301
View directory record Official record
Conditions
Well-Being, Psychological, Psychedelic Experiences
Interventions
Psilocybin, Saline Placebo, Clonidine
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 5:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT07511205
View directory record Official record
Conditions
Healthy Participants, Obesity
Interventions
AZD1043, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137
View directory record Official record
Conditions
Light Chain (AL) Amyloidosis
Interventions
Birtamimab, Placebo, Standard of Care Chemotherapy
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
22
States / cities
North Haven, Connecticut • Trumbull, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

NCT02932969
View directory record Official record
Conditions
Heart Decompensation, Acute
Interventions
BMS-986231, BMS-986231 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 14, 2026, 5:32 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

NCT03139305
View directory record Official record
Conditions
Obesity
Interventions
Glucagon, Placebo
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 5:32 PM EDT
Withdrawn Phase 2 Interventional

Vedolizumab Post Op Study

NCT02834754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, placebo
Drug
Lead sponsor
Marc Schwartz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults

NCT00515385
View directory record Official record
Conditions
West Nile Virus
Interventions
MGAWN1, Placebo
Drug · Other
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

NCT02383589
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Mycophenolate Mofetil Placebo, Mycophenolate Mofetil, Rituximab, Rituximab Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Danavorexton in Anesthetized Adults

NCT05025397
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033, Placebo, Avonex
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

NCT01096043
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Gainesville, Florida • Jacksonville, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 14, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial

NCT00100178
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 14, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

NCT04698915
View directory record Official record
Conditions
SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Interventions
Drug GC4711, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Gilbert, Arizona • Los Angeles, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 14, 2026, 5:32 PM EDT